Edit My Profile

Integrated Search Menu

Search in:

George Poste

Profile photo
Complex Adaptive Systems
Chf Scientist & Regent's Prof
Administrative, TEMPE Campus, Mailcode 9908
Global Futures Scientists and Scholars
Senior Global Futures Scientist
Administrative, TEMPE Campus, Mailcode 9908
Center for Social Dynamics and Complexity (CSDC)
Chief Scientist & Regents Professor
Administrative, TEMPE Campus, Mailcode 9908
School of Life Sciences
Regents Professor
Faculty, TEMPE Campus, Mailcode 9908
Biography: 

Regents Professor George Poste is the Del E. Webb Professor of Health Innovation and chief scientist with the Complex Adaptive Systems Initiative (CASI) at Arizona State University. This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision (personalized) medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009, he directed and built the Biodesign Institute at ASU.

He is a fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a member of the Council for Foreign Relations, and U. S. National Academy of Medicine Board on Global Health. He has served as a member of the Defense Science Board of the U.S. Department of Defense and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.

CV
Binary Data Curriculum Vitae
Education: 
  • D. Sc. University of Bristol, U.K. 1987
  • Ph.D. University of Bristol, U.K. 1969
  • D.V.M. University of Bristol, U.K. 1966
Research Website URL: 
https://casi.asu.edu/
Publications: 
  • Holding the Line on Biodefense State, Local, Tribal, and Territorial Reinforcements Needed A Bipartisan Report of the Blue Ribbon Study Panel on Biodefense. October 2018. https://www.biodefensestudy.org/Holding-the-Line-on Biodefense
  • Blue Ribbon Study Panel on Biodefense. Budget Reform for Biodefense: Integrated Budget Needed to Increase Return on Investment. Blue Ribbon Study Panel on Biodefense: Washington, DC. February 2018
  • Togami, E., J. L. Gardy, G. R. Hansen, G. H. Poste, D. M. Rizzo, M. E. Wilson, and J. A. K. Mazet. 2018. Core Competencies in One Health Education: What Are We Missing? NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC. https://nam.edu/core-competencies-in-one-health-education-what-are-we-missing
  • Domenyuk, V., Gatalica, Z., Santhanam, R., Wei, X., Stark, A. Kennedy, P., Toussaint, B., Levenberg, S., Wang, J., Nianqing, X., Greil, R., Rinnerthaler, G., Gampenrieder, S., Heimberger, A., Berry, D., Barker, A., Quackenbush, J., Marshall, J., Poste, G., Vacirca, J., Vidal, G., Schwartzberg, L., Halbert, D., Voss, A., Magee, D., Miglarese, M., Famulok, M., Mayer, G., and Spetzler, D. “Poly-Ligand Profiling Differentiates Trastuzumab-Treated Breast Cancer Patients According to their Outcomes” Nature Communications (2018)
    DOI: 10.1038/s41467-018-03631-z 
  • MacIntyre, C. R., Engells, T. E., Scotch, M., Heslop, D. J., Gumel, A. B., Poste, G., Chen.  X., Herche, W., Steinhöfel, K., Lim, S., and Broom, A. “Converging and Emerging Threats to Health Security” Environment System Decisions, (2017). https://doi.org/10.1007/s10669-017-9667-0  
  • Alexander, B. M., Ba, S., Berger, M. S., Berry, D. A., Cavenee, W. K., Chang, S. M., Cloughesy, T. F., Jiang, T., Khasraw, M., Li, W., Mittman, R., Poste, G. H., Wen, P. Y., Yung, W. K. A., and Barker, A. D. “Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE” Clinical Cancer Research 24(3) (2017) DOI: 10.1158/1078-0432.CCR-17-0764 
  • Poste, G. (2017). “The Complex Strategic Landscape for Precision Medicine: Cost, Convergence, Culture, Computing and Creative Destruction” Journal of Precision Medicine, 3, 36-51. http://www.thejournalofprecisionmedicine.com/archive-manager/the-complex-strategic-landscape-for-precision-medicine-cost-convergence-culture-computing-and-creative-destruction/
Fall 2020
Course NumberCourse Title
GSC 598Special Topics
Presentations: 

Poste, G.. Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency. Biosecurity and Bioterrorism Response. Stanford University School of Medicine (Jan 23 2019)

Poste, G.. Challenges in Healthcare Innovation in An Era of Technology Acceleration, Convergence and New Value-Based Services. HEALTH CARE LEADERSHIP. Stanford University School of Medicine (Jan 23 2019)

G. Poste. Precision Health and Digital Health: Evolving Inter-Dependencies in the Transformation of Health Care Delivery. Joint University Biomedical Innovation Task Force Meeting. University of Arizona (Tucson) (Oct 15 2018)

G. Poste. Precision Health and Digital Health: Evolving Inter-Dependencies in the Transformation of Health Care Delivery. Joint University Biomedical Innovation Task Force Meeting. Scottsdale (Oct 1 2018)

G. Poste. Cancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment. BIO 302, September 26 – Lecture 10: Special Guest Lecture by Dr. George Poste. School of Life Sciences Building A, Classroom 191 (Sep 26 2018)

G. Poste. Biodefense In The Age of Synthetic Biology and Precision Gene Editing. Global Security PLuS and New Approaches to Grey-Zone Threats. Australia (Sep 11 2018 - Sep 12 2018)

G. Poste. Recorded session: Biodefense In The Age of Synthetic Biology and Precision Gene Editing.. Global Security PLuS and New Approaches to Grey-Zone Threats. Australia (Sep 11 2018 - Sep 12 2018)

G. Poste. Immunophenotyping to Differentiate Responder and Non-Responder Patients in Cancer Immunotherapy. 6th Annual Immuno-Oncology Summit. Boston, MA (Aug 28 2018)

G. Poste. What Needs to Be Done Differently in Cancer Control?. NASEM for Cancer Control in the United States, National Academies of Science, Engineering and Medicine. Washington, DC. Washington, DC (Jun 7 2018)

G. Poste. The Challenge of Comprehensive Cancer Control. NASEM for Cancer Control in the United States, National Academies of Science, Engineering and Medicine. Washington, DC (Jun 6 2018)

Compton, Carolyn. I Won't Rest Until We Have Quality Standards in Place for Biospecimens:. ASU | Mendelspod. Submitted by Ayanna Monteverdi on Tue, 06/05/2018 - 08:34 (Jun 5 2018)

G. Poste. Mapping Complex Biological Information Networks to Develop Robust Biomarkers and Define Phenotypes. NBDA and CAS - Biomedicine* Think Tank II: CONNECTING THE DOTS. Phoenix, AZ (May 21 2018)

G. Poste. Making Precision Medicine A Reality: Molecular Diagnostics, Remote Health Status Monitoring and the Big Data Challenge. Sixth Annual ASU Law GETS Conference. Phoenix, AZ (May 18 2018)

G. Poste. Cancer: A Multi-Dimensional Problem Science, Medicine, Economics, Ethics, Fear and Emotion. BIO302, WEEK 16 - Lecture 24. Tempe Campus in the School of Life Sciences Building A, Classroom 191 (Apr 23 2018)

Poste, G. Precision Health and Digital Health: Evolving Inter-Dependencies in the Transformation of Healthcare Delivery. 9th Siemens Technology and Innovation Council (STIC) Meeting. Farnham Castle, Farnham, UK (Mar 7 2018)

Compton, Carolyn. “Garbage In, Garbage Out.” The Pathologist, (2018) no. 40, pp. 18–27. (Mar 1 2018)

Carolyn Compton. Specimens, Standards, and Signatures: Keys to the Vision of Precision Medicine. ISBER 2018 | Luxembourg Symposium. EUROPEAN CONVENTION CENTER LUXEMBOURG (ECCL) (Feb 27 2018)

G. Poste. Cancer as a Complex Adaptive System: Cancer Progression, Evolutionary Dynamics and Implications for Treatment. BIO 302, Lecture 12. ASU Tempe Campus, School of Life Sciences Building A, Classroom 191 (Feb 26 2018)

Poste, G. Biosecurity: A Multi-Dimensional Challenge of Escalating Complexity and Urgency. Biosecurity and Bioterrorism Response, Winter 2018 Course. Stanford University School of Medicine (Jan 24 2018)

Poste, G.. Wearables, Apps and Big Data in the Age of Precision Medicine. Spring 2018/Study Group on Biological Revolutions. Center for Law, Science and Technology (Jan 11 2018)

Visit http://www.casi.asu.edu/presentations/ for full list of presentations 

Honors / Awards: 
  • 1997 F.R.S.Elected Fellow, The Royal Society, London, England

  • 1999 C.B.E. Commander of the Order of the British Empire, Honours List, H.M. Queen

  • 2004 Award, Recipient of Scientist of the Year Award, R&D Magazine

  • 2006 Award, Einstein Award, Global Business Leadership Forum

  • 2009 Award, Scrip Lifetime Achievement Award from Pharmaceutical Industry Leadership Forum

  • 2013 Award, Recipient of the American Association of Clinical Chemistry (AACC) Outstanding Speaker  

  • 2015  Award, Listed in Scientific American 7th Annual WorldVIEW Scorecard Top 100 most influential people in                         biotechnology. June 2015

  • 2016 Award, Arizona Bioindustry Association Pioneer Award for Lifetime Achievement  
     

Editorships: 
  • 1985 – 1996 Founder and Member, Editorial Board, Cancer and Metastasis Reviews 
  • 1987 – 1995 Member, Editorial Board, Cancer Invasion and Metastasis
  • 1987 – 1999 Member, Editorial Board, Drug Targeting and Delivery
  • 1988 – 1995 Member, Editorial Board, Clinical and Experimental Metastasis
  • 1989 – 1999 Member, Editorial Board, International Journal of Pharmaceutics
  • 1990 – 1998 Member, Editorial Board, Journal of Drug Targeting 
  • 1992 – 1999 Member, Editorial Board, Advanced Drug Delivery Reviews
  • Current  Member, Editorial Board, Nature Bio/Technology
  • Current  Member, Editorial Board, Current Opinion in Biotechnology
  • Current  Member, Editorial Board, Expert Opinion on Investigational Drugs 
  • Current  Member, Senior Advisory Panel, Current Drugs 
  • Current  Member, Editorial Board, Pharmacogenomics
  • Current  Member, Editorial Board, Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science
  • Current  Member, Editorial Board, Expert Opinion on Molecular Diagnostics
  • Current  Member, Editorial Board, BioTechniques
  • Current  Member, Editorial Board, Health Security, Mary Ann Liebert, Inc.
Professional Associations: 

Council for Foreign Relations

Elected Fellow, The Academy of Medical Sciences, London, England

Service: 
  • Sloan Foundation Expert Advisory Group on Influenza Pandemic Preparedness, Member (2009 - Present)
  • Synthetic Genomics, Scientific Advisory Board (2009 - Present)
  • Editorial Board, Bioterrorism and Biosecurity, Member (2008 - Present)
  • Caris Life Sciences, Vice Chairman (2005 - Present)
  • Burrill and Company, Advisory Board (2004 - Present)
  • Exelixis, Board Member (2004 - Present)
  • Exelixis, Board Member (2004 - Present)
  • Monsanto, Board Member (2003 - Present)
  • The Institute of Medicine of The National Academies, Forum on Microbial Threats, Member (2003 - Present)
  • Orchid Biosciences, Chairman (2002 - Present)
  • Defense Health Board, US Department of Defense, Member (2008 - 2009)
  • Defense Science Board, US Department of Defense, Member (2003 - 2009)
  • Orchid Biosciences, Chairman (2002 - 2009)
  • Sloan Foundation Task Force on Synthetic Biology, Member (2008 - 2008)
  • The Institute of Medicine of The National Academies, Committee Member (2006 - 2006)
  • Institute of Medicine of The National Academies, Committee Member (2005 - 2006)
  • Institute of Medicine: National Research Council, US National Academy of Sciences, Member (2005 - 2006)
  • The Institute of Medicine of The National Academies, Committee Member (2005 - 2005)
  • Threat Reduction Advisory Committee, United States Department of Defense, Member (2001 - 2005)
  • AdvancePCS, Board Member (2002 - 2003)
  • Board of Trustees; The International Vaccine Institute, Seoul, Korea, Member (2000 - 2003)
  • Illumina, Board Member (2000 - 2003)
  • Maxygen, Board Member (2000 - 2003)
  • Structural GenomiX, Chairman (2000 - 2003)
  • diaDexus, Chairman (1997 - 2003)
  • Governing Board, Beckman Center for Molecular and Genetic Medicine, Stanford University, Member (1993 - 2003)
  • Financial Times Annual Biotechnology Conference London, Chair (2003 - 2003)
  • Rand Critical Technologies Task Force on The Hybrid Carbon Silicon Brain, Committee Member (1998 - 2001)
  • Rand Critical Technologies Task Force on The Hybrid Carbon Silicon Brain, Member (1998 - 2001)
  • BP Technology Advisory Council, Member (1998 - 2000)
  • Board of Medical Governors, World Economic Forum, Davos, Member (1998 - 2000)
  • Advisory Committee on International Economic Policy, United States State Department, Member (Present)
  • Biological Weapons Working Group, National Academy of Sciences, Member (Present)
  • Board of Trustees; The International Vaccine Institute, Seoul, Korea, Member (Present)
  • Board on Global Health, National Academy of Sciences Institute of Medicine, Member (Present)
  • Committee on Advances in Technology and Next Generation Biowarfare Threats. Institute of Medicine: National Research Council, US National Academy of Sciences, Member (Present)
  • Defense Science Board, United States Department of Defense, member (Present)
  • Editorial Board, Bioterrorism and Biosecurity, Member (Present)
  • Editorial Board, Current Opinion in Biotechnology, Member (Present)
  • Editorial Board, Expert Opinion on Investigational Drugs, Member (Present)
  • Editorial Board, Expert Opinion on Molecular Diagnostics, Member (Present)
  • Editorial Board, Journal of Commercial Biotechnology, Member (Present)
  • Editorial Board, Nature Bio/Technology, Member (Present)
  • Editorial Board, Pharmacogenomics, Member (Present)
  • Editorial Board, Polymers in Medicine and Biotechnology, Member (Present)
  • Editorial Board, The Journal of Biolaw and Business, Member (Present)
  • Senior Advisory Panel, Current Drugs, Member (Present)
Expertise Areas: 
Cancer
Cellular Microenvironment
HIV, STI and Infectious Diseases
Microbiology
Veterinary